Brii Biosciences - About the company
Brii Biosciences is a public company based in San Francisco (United States), founded in 2018 by Zhi Hong. It operates as a Developer of biologics to treat hepatitis B infection. Brii Biosciences has raised $415M in funding from investors like Invesco, Arch Venture Partners and Yunfeng Capital. The company has 388 active competitors, including 107 funded and 95 that have exited. Its top competitors include companies like HOOKIPA Pharma, Atea and ImmunityBio.
Company Details
Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
- Website
- briibio.com
- Email ID
- *****@briibio.com
- Registered Address
- Durham, North Carolina
Key Metrics
Founded Year
2018
Location
San Francisco, United States
Stage
Public
Total Funding
$415M in 3 rounds
Latest Funding Round
Ranked
6th among 388 active competitors
Employee Count
84 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Brii Biosciences
Brii Biosciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
BRII BIOSCIENCES CIN: 824071667 , United States, Active | Dec 26, 999 | - | 25 (As on Dec 31, 2024) | - |
Brii Biosciences's IPO details
Brii Biosciences got listed on Jul 13, 2021.
Click here to take a look at Brii Biosciences's IPO in detail
Sign up to download Brii Biosciences' company profile
Brii Biosciences's funding and investors
Brii Biosciences has raised a total funding of $415M over 3 rounds. Its first funding round was on May 25, 2018. Brii Biosciences has 9 institutional investors.
Here is the list of recent funding rounds of Brii Biosciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 07, 2021 | 8456835 | Post IPO | 7440066 | 8633795 | 9109904 | 7778899 |
Mar 23, 2021 | 2484068 | Series D | 2856364 | 5924178 | 3622313 | |
May 25, 2018 | 8576046 | Series D | 1516413 | 4325858 | 7864492 |
View details of Brii Biosciences's funding rounds and investors
Brii Biosciences' founders and board of directors
Founder? Claim ProfileHere are the details of Brii Biosciences' key team members:
- Zhi Hong: Co-Founder & CEO of Brii Biosciences.
View details of Brii Biosciences's Founder profiles and Board Members
Brii Biosciences' employee count trend
Brii Biosciences has 84 employees as of Sep 26. Here is Brii Biosciences's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Brii Biosciences's Competitors and alternates
Top competitors of Brii Biosciences include HOOKIPA Pharma, Atea and ImmunityBio. Here is the list of Top 10 competitors of Brii Biosciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | HOOKIPA Pharma 2011, Vienna (Austria), Public | Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 70/100 | |
2nd | Atea 2014, Boston (United States), Public | Developer of therapeutics for viral diseases | $293M | 67/100 | |
3rd | ImmunityBio 2014, El Segundo (United States), Public | Developer of peptide-based vaccines for immunotherapy | $169M | 67/100 | |
4th | Vaxart 2004, San Francisco (United States), Public | Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 67/100 | |
5th | Tonix Pharma 2007, New York City (United States), Public | Developer of next-generation medicines for CNS and immunological disorders | $4.45M | 66/100 | |
6th | Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
7th | Developer of vaccines against constantly mutating pathogens | $42.2M | 63/100 | ||
8th | Leyden Labs 2020, Leiden (Netherlands), Series B | Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $303M | 63/100 | |
9th | Ascletis Pharma 2011, Hangzhou (China), Public | Developer of small molecules for the treatment of multiple diseases | $255M | 62/100 | |
10th | eradivir 2020, West Lafayette (United States), Series A | Developer of immunotherapies for the treatment of infectious diseases | $20.4M | 62/100 |
Looking for more details on Brii Biosciences's competitors? Click here to see the top ones
Brii Biosciences's Investments and acquisitions
Brii Biosciences has a total of 1 investment in AN2 Therapeutics. Brii Biosciences has not made any acquisitions as of now.Reports related to Brii Biosciences
Here is the latest report on Brii Biosciences's sector:
News related to Brii Biosciences
Media has covered Brii Biosciences for a total of 6 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.
•
•
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsPR Newswire•Aug 21, 2026•Brii Biosciences
•
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis BPR Newswire•Jul 03, 2026•Brii Biosciences, Vir Biotechnology
•
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026PR Newswire•Apr 26, 2026•Brii Biosciences
•
Susannah Cantrell Joins Ossium Health as Chief Commercial OfficerBusiness Wire•Nov 20, 2025•Brii Biosciences, Ossium Health
•
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial ResultsPR Newswire•Aug 21, 2025•Brii Biosciences
•
Brii Biosciences Licenses BRII-693 Rights to Joincare Group in Greater ChinaPR Newswire•Jul 04, 2025•Brii Biosciences, JoinCare
•
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsPR Newswire•Mar 21, 2025•Brii Biosciences, Vir Biotechnology
•
Durham firm acquires hepatitis B drug from defunct companyThe Business Journals•Jan 02, 2025•Brii Biosciences
•
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH StudyPR Newswire•Dec 31, 2024•Brii Biosciences, VBI Vaccines, K2 HealthVentures
Are you a Founder ?
FAQs about Brii Biosciences
Explore our recently published companies
- Way - Helsinki based, 2024 founded, Seed company
- Delite - Hyderabad based, 2010 founded, Unfunded company
- Yuki - Tel Aviv based, 2023 founded, Seed company
- Hedgepointcapital.com - 2021 founded, Funding Raised company
- MicroRoboTech - Hangzhou based, 2025 founded, Series A company
- Semper Plugins - Durham based, 2011 founded, Acquired company
